A Phase Ib Clinical Study for rhTPO in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease

Exclusion Criteria

• •Those who are known to be allergic to any component of this product.
• •Patients with liver cirrhosis caused by drug-induced liver damage.
• •Those with a history of splenectomy or liver transplantation.
• •Previously or currently suffering from serious diseases of any organ or system other than the liver, including cardiovascular disease, blood system disease, and nervous system disease patients, as well as any other diseases judged by the investigator to be unsuitable for participating in this trial.
• •Currently suffering from malignant tumors, including solid tumors and hematological malignancies.
• •Those who are clearly diagnosed as liver failure.
• •Liver cirrhosis with serious complications, including: hepatic encephalopathy, refractory ascites, upper gastrointestinal bleeding, etc.;.
• •People who have previously or are currently suffering from any disease that may lead to reduced platelet count and/or abnormal platelet function except for chronic liver disease and cirrhosis, including aplastic anemia, myelodysplastic syndrome, myelofibrosis, etc.
• •Those who have undergone intrahepatic portosystemic shunt via jugular vein in the past.
• •Doppler ultrasound, computerized tomography (CT) or magnetic resonance imaging (MRI) and other imaging examinations that indicate the presence of portal vein thrombosis within 28 days before administration.
• •Use heparin, warfarin, non-steroidal anti-inflammatory drugs, aspirin, verapamil, and ticlopidine or glycoprotein IIb/IIIa antagonist (such as tirofiban) within 7 days before administration treat.
• •Interferon has been used within 14 days before administration.
• •Have received platelet transfusion or used platelet-containing blood products within 14 days before administration, except for transfusion of concentrated red blood cells.
• •Those who have received any platelet-increasing therapy within 28 days before administration (the platelet-increasing function of Li Kejun, caffeic acid tablets and/or certain Chinese medicines or Chinese patent medicines that have the function of increasing platelet function can be accepted within 14 days), including but not Limited to rhTPO.
• •No more than 28 days after the cessation of other research drug treatments or device research treatments carried out before the administration.
• •There are currently patients with WHO ≥ Grade 2 active bleeding, or those with active bleeding in the past 2 weeks.
• •Known human immunodeficiency virus positive or Treponema pallidum antibody positive.
• •Combined with severe infections that cannot be effectively controlled (except for chronic hepatitis B and chronic hepatitis C).
• •The subjects did not agree to take effective contraceptive measures during the trial period. The female subjects had a positive blood pregnancy test during the screening period; women who were pregnant or breastfeeding or had pregnancy plans within 3 months.
• •Subjects' understanding, communication and cooperation are not enough to guarantee that the research will be carried out in accordance with the protocol.
• •The researcher believes that the subjects are not suitable to participate in this study due to other reasons.